SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: forgetme3/16/2025 2:00:25 PM
   of 63304
 
biolata Tce program will have data at asco. Co has disclosed mtd has not been reached. There have been report of tumor shrinkage and 1 colon cancer pt has stable disease for a year. At 34 cents, worth the gamble?
amgen epcam data trial was terminated because of toxicty and biolata tce was supposed to be safer. Also vir her2 tce did show 33 percent response rate on her2 colon cancer pt. These may implies t cell engagememt does work if the toxicty is solved. Biolata tce construct is different where full antibody was used instead of fragment and have longer half life. Do yr DD!
Amgen Epcam Tce :Solitomab, a bispecific T-cell engager (BiTE@) antibody construct targeting EpCAM • Sixty-five patients received solitomab at doses between 1 and 96 ug/day for 228 days • Overall, 95% of patients had grade >3 treatment-related AEs, primarily diarrhea, elevated liver parameters, and elevated lipase • Fifteen patients had dose-limiting toxicities (DLTs): • had transient abnormal liver parameters shortly after infusion start or dose escalation (grade 3, n grade 4, n = 4) • One had supraventricular tachycardia (grade 3) • Six patients had a DLT of diarrhea: (grade 3, n = 4; grade 4, n = 1; grade 5, n = 1) • Limited anti-tumor activity • 1 unconfirmed partial response • 17 stable disease • 28 disease progression

https://www.bioatla.com/wp-content/uploads/2024/03/A-novel-conditional-active-biologic-anti-EpCAM-x-anti-CD3-bispecific-antibody-with-synergistic-tumor-selectivity-for-cancer-immunotherapy.pdf
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News